Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 53Breast Neoplasms 26Lung Neoplasms 21Triple Negative Breast Neoplasms 16Neoplasm Metastasis 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 14Colorectal Neoplasms 14Head and Neck Neoplasms 12Esophageal Neoplasms 12Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Small Cell Lung Carcinoma 10Rectal Neoplasms 9Ovarian Neoplasms 8Leukemia, Myeloid, Acute 8Recurrence 7Nasopharyngeal Carcinoma 7Glioblastoma 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Mouth Neoplasms 4Lymphoma 4Endometrial Neoplasms 4Colonic Neoplasms 4

Interventions

endostar protein 1Surgical Procedures, Operative 1Endostatins 1Drug Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unresectable Non-small Cell Lung Cancer × Drug Therapy × 1 year × Clear all
NCT06617936 2025-07-15

Tislelizumab Combined With Recombinant Human Endostatin Combined With Chemotherapy for Unresectable Stage III Non-small Cell Lung Cancer.

Shandong Public Health Clinical Center

Phase 2 Recruiting
36 enrolled
Thoracic

Unresectable Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡